OTTO

Otto Therapeutics is a San Francisco-based biotechnology company dedicated to developing transformative RNA-based therapies for neurodegenerative diseases. Founded by renowned scientists from the Gladstone Institutes and backed by premier investors including ARCH Venture Partners and GV, the company focuses on modulating RNA expression to address the root causes of genetic disorders such as Huntington's disease and amyotrophic lateral sclerosis (ALS). By utilizing small molecule approaches to target RNA, Otto Therapeutics aims to create disease-modifying treatments that can cross the blood-brain barrier more effectively than traditional biologics. The company operates primarily in a pre-clinical stage, advancing a pipeline of precision medicines for high-unmet-need CNS indications.